On March 31, 2025, Eterna Therapeutics Inc. entered a securities purchase agreement to sell 58,262,918 shares at $0.1046 each and pre-funded warrants for 11,048,736 shares at $0.0996 each, with the first closing on April 2, 2025, selling 9,934,016 shares and 509,736 warrants. The company also rescheduled its 2025 annual meeting to June 2, 2025, requiring stockholder proposals by April 13, 2025.